After completing its latest deal with Eli Lilly & Co. on its ultra-fast acting insulin, BioChaperone Lispro, France’s Adocia SAS will now accelerate its work on combination insulin therapies and other BioChaperone formulations.
“The potential benefits of combining insulins with the BioChaperone technology are almost as high as the potential of our ultra-fast-acting